首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis.
【24h】

Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis.

机译:甲状腺转录因子-1肺腺癌组织扩增和表达和胸腔积液预测患者存活和预后。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Thyroid transcription factor-1 (TTF1) plays a role in lung adenocarcinoma development. We investigated the significance of TTF1 in primary lung adenocarcinomas, lymph node metastases, and malignant pleural effusions (MPEs). METHODS: We studied TTF1 in 175 primary lung adenocarcinomas, 52 lymph node metastases, and 46 MPE using microarray-based fluorescence in situ hybridization, immunohistochemistry, and messenger RNA (mRNA) in situ hybridization. Real-time reverse transcription polymerase chain reaction was used to investigate correlations between TTF1 amplification and mRNA expression. Correlations between clinicopathologic characteristics, TTF1 amplification, TTF1 expressions, overall survival, and prognosis were analyzed. RESULTS: TTF1 was amplified in 7% of primary lung adenocarcinomas, 4% of lymph node metastases, and 4% of MPE. TTF1 amplification in lung adenocarcinomas was associated with pathologic subtypes (p = 0.029). Patients with positive TTF1 protein and mRNA expressions had improved overall survival if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). A multivariate model did not show patients with positive TTF1 expressions tended to have better prognoses if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). Survival time was longer for patients with TTF1 expressions in both primary lung tissues (p < 0.001) and MPE (p = 0.045). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma (p < 0.001). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma tissues (p < 0.001) while not in MPE (p = 0.058). TTF1 mRNA level was higher in cases with TTF1 amplification compared with those without TTF1 amplification. CONCLUSIONS: Patients with lung adenocarcinoma without TTF1 amplification tend to have better prognoses than those with TTF1 amplification in cases with positive TTF1 expressions. Positive TTF1 expressions in lung adenocarcinoma tissues are favorable prognostic parameters in patients with lung adenocarcinoma.
机译:介绍:甲状腺转录因子-1(TTF1)在肺腺癌发育中起作用。我们研究了TTF1在原发性肺腺癌,淋巴结转移和恶性胸腔积液(MPE)中的意义。方法:通过原位杂交,免疫组化和信使RNA(mRNA)研究了175名原发性肺腺癌,52个淋巴结转移,52个淋巴结转移和46MPe的TTF1和46MPe。实时逆转录聚合酶链反应研究TTF1扩增与mRNA表达之间的相关性。分析了临床病理特征,TTF1扩增,TTF1表达,整体存活和预后之间的相关性。结果:TTF1以7%的原发性肺腺癌,4%的淋巴结转移和4%的MPE中扩增。 TTF1在肺腺癌中的扩增与病理亚型相关(P = 0.029)。患有阳性TTF1蛋白和mRNA表达的患者在与具有TTF1扩增(P = 0.068)相比的TTF1无言比的情况下,如果TTF1毫无重解,则在整体存活中得到改善(P = 0.068)。多变量模型未显示患者,呈阳性TTF1表达趋势,如果TTF1与TTF1扩增的那些(P = 0.068)相比,如果TTF1未取代,则往往具有更好的预测。在原发性肺组织(P <0.001)和MPE中的TTF1表达患者(P = 0.045)中,存活时间更长。多变量模型证实了肺腺癌TTF1表达的预后值(P <0.001)。多变量模型证实了TTF1表达在肺腺癌组织中的预后值(P <0.001),而不是在MPE中(P = 0.058)。在与没有TTF1扩增的情况相比,TTF1 mRNA水平较高。结论:没有TTF1扩增的肺腺癌患者倾向于比具有阳性TTF1表达式的TTF1扩增的患者更好的预后。肺腺癌组织中的阳性TTF1表达是肺腺癌患者的良好预后参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号